Quick Takeaways
- Whitefort Capital Management, LP filed SCHEDULE 13D/A for Arbutus Biopharma Corp Common Shares, without par value (ABUS).
- Disclosed ownership: 8%.
- Date of event: 24 Apr 2026.
Quoteable Key Fact
"Whitefort Capital Management, LP disclosed 8% ownership in Arbutus Biopharma Corp Common Shares, without par value (ABUS) on 24 Apr 2026."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP | 8% | 15,794,261 | 0 | 15,794,261 | /s/ David Salanic | David Salanic, Co-Managing Member of Whitefort Capital GP, LLC, its General Partner | 0001704387 |
| Whitefort Capital GP, LLC | 8% | 15,794,261 | 0 | 15,794,261 | /s/ David Salanic | David Salanic, Co-Managing Member | |
| Whitefort Capital Management, LP | 8% | 15,794,261 | 0 | 15,794,261 | /s/ David Salanic | David Salanic, Co-Managing Partner | 0001884931 |
| Whitefort Capital Management GP, LLC | 8% | 15,794,261 | 0 | 15,794,261 | /s/ David Salanic | David Salanic, Co-Managing Member | |
| David Salanic | 8% | 15,794,261 | 0 | 15,794,261 | /s/ David Salanic | David Salanic | |
| Joseph Kaplan | 8% | 15,794,261 | 0 | 15,794,261 | /s/ Joseph Kaplan | Joseph Kaplan |